TITLE

Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma

AUTHOR(S)
Jianfei Huang; Xialing Zhang; Qi Tang; Feng Zhang; Yuhua Li; Zhenqing Feng; Jin Zhu
PUB. DATE
April 2011
SOURCE
Journal of Clinical Pathology;Apr2011, Vol. 64 Issue 4, p343
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background Vascular endothelial growth factor receptor 2 (VEGFR2) has been suggested to play an important role in solid tumours. Although several reports have shown the relationship between VEGFR2 expression and hepatocellular carcinoma (HCC), the expression pattern of VEGFR2 in HCC parenchyma or stroma, as well as the relationship between VEGFR2 expression and clinicopathological characteristics in HCC, are yet to be satisfactorily defined. Methods One-step real-time PCR, western blotting and immunohistochemistry were used to characterise the expression of VEGFR2 in HCC using a self-made anti-VEGFR2 monoclonal antibody (A8H1). Results Expression of VEGFR2 in HCC cells was higher than in hepatic cells (p<0.001). Comparison of clinicopathological characteristics and immunohistochemistry by ?2 test analysis showed that the high expression of VEGFR2 in HCC was related to large tumour diameter (p=0.012), poor differentiation (p=0.007), high serum α-fetoprotein (p=0.029), multifocal gross classification (p=0.007), and less than 5⇔…years' survival (p=0.029). Kaplan-Meier survival and Cox regression analyses showed that high VEGFR2 expression (p=0.009) and stage grouping with TNM classification (p=0.004) were independent prognotic factors. Conclusions The efficacy of A8H1 in immunohistochemistry using HCC tissues was confirmed. There was a correlation of high VEGFR2 expression with prognostic significance in HCC. Additionally, the self-made anti-VEGFR2 monoclonal antibody could be used for future anti-HCC-targeted therapy research.
ACCESSION #
60944509

 

Related Articles

  • Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Yoshiji, H.; Kuriyama, S.; Noguchi, R.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Ktade, M.; Uemura, M.; Masaki, T.; Fukui, H. // Gut;Dec2005, Vol. 54 Issue 12, p1768 

    Background: Orchestration of two major classes of angiogenic factors-namely, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2)-has been shown to play a pivotal role in tumour angiogenesis, including hepatocellular carcinoma (HCC). However, few studies have focused on the...

  • Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor - 3. Karnani, Päivi; Kairemo, Kalevi; Paakkari, Ilari // Current Radiopharmaceuticals;Jan2010, Vol. 3 Issue 1, p60 

    Biodistribution of the monoclonal antibody (mAb 9d9f9) against the vascular endothelial growth factor receptor-3 (VEGFR-3) is studied here in the rat. VEGFR-3 is expressed on endothelial cells of lymphatic endothelium during the tissue growth. The mAb9d9f9 is the first specific molecular marker...

  • Anti-Implantation Strategies for Contraception.  // Fertility Weekly;6/27/2005, p1 

    Studies the three target-oriented anti-implantation strategies for contraception. Application of monoclonal antibody to vascular endothelial growth factor (VEGF) during the peri-implantation period; Approach used in the investigation of the use of leukemia inhibitory factor; Ability of VEGF to...

  • Soluble Vascular Endothelial Growth Factor Decoy Receptor FP3 Exerts Potent Antiangiogenic Effects. Yu, De-Chao; Lee, Jung-Sun; Yoo, Ji Young; Shin, Hyewon; Deng, Hongxin; Wei, Yuquan; Yun, Chae-Ok // Molecular Therapy;May2012, Vol. 20 Issue 5, p938 

    The binding of vascular endothelial growth factor (VEGF) to its receptors stimulates tumor growth; therefore, modulation of VEGF would be a viable approach for antiangiogenic therapy. We constructed a series of soluble decoy receptors containing different VEGF receptor 1 (FLT1) and VEGF receptor...

  • Resistance—the true face of biological defiance. Emami-Shahri, Nia; Hagemann, Thorsten // Rheumatology;Mar2012, Vol. 51 Issue 3, p413 

    Biological therapeutics are widely used in chronic inflammatory and malignant disease. The underlying mechanisms of treatment failure for these drugs are poorly understood. Resistance to these biological agents and the further subdivision into intrinsic and acquired resistance are not clearly...

  • The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials. Wang, Kai; Qu, Xiao; Wang, Ying; Dong, Wei; Shen, Hongchang; Zhang, Tiehong; Ni, Yang; Liu, Qi; Du, Jiajun // Clinical Drug Investigation;Jan2016, Vol. 36 Issue 1, p27 

    Background and Objectives: Ramucirumab is a fully immunoglobulin G (lgG) monoclonal antibody targeting vascular endothelial growth factor receptor type 2 (VEGFR2). Previous clinical trials suggested ramucirumab could improve the survival and increase the risk of adverse effects. Here, we aimed...

  • Comparative Analysis of Hepatocellular Carcinoma in Men and Dogs. Grabarević, Željko; Ćorić, Marijana; Seiwerth, Sven; Džaja, Petar; Artuković, Branka; Kurilj, Andrea Gudan; Beck, Ana; Hohšteter, Marko; Šoštarić-Zuckermann, Ivan-Conrado; Brčić, Luka; Hrstić, Irena // Collegium Antropologicum;Sep2009, Vol. 33 Issue 3, p811 

    Concerning the important differences in the ethiopathology of hepatocelular carcinomas (HCC) in humans and dogs, our work describes the expression of epidermal growth factor receptor (EGFr), cytokeratine 19 (CK19), vascular endothelial growth factor (VEGF) and transforming growth factor beta...

  • VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. Zhang, Lei; Wang, Jia-Ning; Tang, Jun-Ming; Kong, Xia; Yang, Jian-Ye; Zheng, Fei; Guo, Ling-Yun; Huang, Yong-Zhang; Zhang, Li; Tian, Lin; Cao, Shu-Fen; Tuo, Chang-Hai; Guo, Hong-Li; Chen, Shi-You // Molecular Biology Reports;May2012, Vol. 39 Issue 5, p5085 

    Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis. VEGF induces new vessel formation and tumor growth by inducing mitogenesis and chemotaxis of normal endothelial cells and increasing vascular permeability. However, little is known about VEGF function in the...

  • Non-thermal Effects of Far-Infrared Ray (FIR) on Human Hepatocellular Carcinoma Cells HepG2 and their Tumors. Ishikawa, Tatsuo; Ishibashi, Jun; Yamashita, Kikuji; Dalkhsuren, Shine-Od; Sumida, Kaori; Masui, Takahumi; Kitamura, Seiichiro // Journal of Cancer Science & Therapy;Dec2009, Vol. 1 Issue 2, p1 

    We detected an efficacy of Far-Infrared Ray ( FI R) on HepG2 cell lines and their implanted cancer tumors by using an incubator and a murine raising rack which irradiate FIR at the wavelength of it was 4-20μm t hat we developed. In this study we used hepatocytometer, WST-1 assay and Brd-U...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics